Lucy Flanders, Consultant Medical Oncologist at Royal Free London NHS Foundation Trust, shared on X:
“Can we prevent pancreatic cancer before it starts?
In models of PDAC, RAS(ON) inhibitors
- regressed premalignant lesions
- delayed tumor onset
- increased survival
A compelling rationale for exploring KRAS-targeted interception to prevent PDAC.
Translation to humans remains key challenge.”
Read the full article.
Article: Cancer interception with KRAS inhibitors in preclinical models of pancreatic ductal adenocarcinoma
Authors: Minh T. Than, Lucie Dequiedt, Rina Sor, Shreya Nair, Nune Markosyan, Emma E. Furth, Chenghua Yang, Courtney Ray-Fofana, Marie Menard, Elsa Quintana, A. Cole Edwards, Connor J. Hennessey, Austin L. Good, Liz Quinones, Yunseo Hwang, Cynthia Clendenin, Ashley L. Kiemen, Robert H. Vonderheide, Ben Z. Stanger
Read more on this topic:
Phase 3 RASolute 309 Trial Begins: RASONQUE Plus Zoldonrasib in First-Line RAS G12D PDAC